RU2012118140A - METHOD FOR INDIVIDUAL PURPOSE OF SYSTEM PULSE THERAPY BY Glucocorticosteroids to PATIENTS WITH ENDOCRINE OPHTHALMopathy - Google Patents

METHOD FOR INDIVIDUAL PURPOSE OF SYSTEM PULSE THERAPY BY Glucocorticosteroids to PATIENTS WITH ENDOCRINE OPHTHALMopathy Download PDF

Info

Publication number
RU2012118140A
RU2012118140A RU2012118140/15A RU2012118140A RU2012118140A RU 2012118140 A RU2012118140 A RU 2012118140A RU 2012118140/15 A RU2012118140/15 A RU 2012118140/15A RU 2012118140 A RU2012118140 A RU 2012118140A RU 2012118140 A RU2012118140 A RU 2012118140A
Authority
RU
Russia
Prior art keywords
glucocorticosteroids
patients
pulse therapy
endocrine ophthalmopathy
protein content
Prior art date
Application number
RU2012118140/15A
Other languages
Russian (ru)
Other versions
RU2503011C1 (en
Inventor
Дмитрий Михайлович Серкин
Ольга Владимировна Серебрякова
Михаил Анатольевич Серкин
Светлана Владимировна Харинцева
Владимир Вячеславович Харинцев
Вера Ивановна Просяник
Original Assignee
Государственное бюджетное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Министерства здравоохранения и социального развития
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное бюджетное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Министерства здравоохранения и социального развития filed Critical Государственное бюджетное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Министерства здравоохранения и социального развития
Priority to RU2012118140/15A priority Critical patent/RU2503011C1/en
Publication of RU2012118140A publication Critical patent/RU2012118140A/en
Application granted granted Critical
Publication of RU2503011C1 publication Critical patent/RU2503011C1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Способ индивидуального назначения системной пульс-терапии глюкокортикостероидами пациентам с эндокринной офтальмопатией, включающий балльную оценку жалоб и объективного состояния больных, отличающийся тем, что по шкале CAS оценивают активность заболевания, определяют содержание белка теплового шока 90 в сыворотке крови и при активности эндокринной офтальмопатии 3 балла и более и содержании белка теплового шока 90 менее 38 нг/мл назначают системную пульс-терапию глюкокортикостероидами.The method of individual prescribing systemic pulse therapy with glucocorticosteroids to patients with endocrine ophthalmopathy, including a scoring of complaints and an objective state of patients, characterized in that the disease activity is assessed on a CAS scale, the serum heat shock protein content is determined in blood serum, and 3 points in case of endocrine ophthalmopathy activity and more and a heat shock protein content of 90 less than 38 ng / ml is prescribed systemic pulse therapy with glucocorticosteroids.

Claims (1)

Способ индивидуального назначения системной пульс-терапии глюкокортикостероидами пациентам с эндокринной офтальмопатией, включающий балльную оценку жалоб и объективного состояния больных, отличающийся тем, что по шкале CAS оценивают активность заболевания, определяют содержание белка теплового шока 90 в сыворотке крови и при активности эндокринной офтальмопатии 3 балла и более и содержании белка теплового шока 90 менее 38 нг/мл назначают системную пульс-терапию глюкокортикостероидами. The method of individual prescribing systemic pulse therapy with glucocorticosteroids to patients with endocrine ophthalmopathy, including a scoring of complaints and an objective state of patients, characterized in that the disease activity is assessed on a CAS scale, the serum heat shock protein content is determined in blood serum, and 3 points in case of endocrine ophthalmopathy activity and more and a heat shock protein content of 90 less than 38 ng / ml is prescribed systemic pulse therapy with glucocorticosteroids.
RU2012118140/15A 2012-05-03 2012-05-03 Method for individual prescription of systemic glucocorticosteroid pulse therapy in patients with endocrinal ophthalmopathy RU2503011C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2012118140/15A RU2503011C1 (en) 2012-05-03 2012-05-03 Method for individual prescription of systemic glucocorticosteroid pulse therapy in patients with endocrinal ophthalmopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012118140/15A RU2503011C1 (en) 2012-05-03 2012-05-03 Method for individual prescription of systemic glucocorticosteroid pulse therapy in patients with endocrinal ophthalmopathy

Publications (2)

Publication Number Publication Date
RU2012118140A true RU2012118140A (en) 2013-11-10
RU2503011C1 RU2503011C1 (en) 2013-12-27

Family

ID=49516654

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012118140/15A RU2503011C1 (en) 2012-05-03 2012-05-03 Method for individual prescription of systemic glucocorticosteroid pulse therapy in patients with endocrinal ophthalmopathy

Country Status (1)

Country Link
RU (1) RU2503011C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742188C1 (en) * 2020-07-22 2021-02-03 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Method for the treatment of optic neuropathy in patients with edematous exophthalmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340901C1 (en) * 2007-07-25 2008-12-10 Валерий Федорович Экгардт Method of predicting of development of autoimmune ophthalmopathy
RU2421194C2 (en) * 2009-08-12 2011-06-20 Федеральное государственное учреждение (ФГУ) Эндокринологический научный центр Росмедтехнологий Method of diagnosing endocrine ophthalmopathy

Also Published As

Publication number Publication date
RU2503011C1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
MX2014016014A (en) Methods for determining drug efficacy using cereblon-associated proteins.
EA201690746A1 (en) TREATMENT WITH THE USE OF BLUTON AND IMMUNOTHERAPY THYROZINKINASE INHIBITORS
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
FI20115670A0 (en) In vitro cardiovascular model
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
RU2012118140A (en) METHOD FOR INDIVIDUAL PURPOSE OF SYSTEM PULSE THERAPY BY Glucocorticosteroids to PATIENTS WITH ENDOCRINE OPHTHALMopathy
WO2014169011A3 (en) Methods for treating immune diseases
WO2016170187A3 (en) Biomarkers for determining the clinical response to cell therapy
ES2481517A2 (en) Method for the diagnosis of parkinson's disease in early stages (Machine-translation by Google Translate, not legally binding)
RU2015152386A (en) Blood circulation simulator
UA104713U (en) A method of predicting acute coronary syndrome in patients with stable coronary heart disease
RU2012123184A (en) METHOD FOR CONTROLLED REDUCTION OF THE AGGREGATION ACTIVITY OF THROMBOCYTES BY MEXIDOL IN THE EXPERIMENT
RU2012126189A (en) METHOD FOR CREATING A DYNAMIC MODEL OF CHRONIC HEART INSUFFICIENCY
UA94058U (en) Method for diagnosing fracture healing
RU2013115182A (en) METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD
RU2012110490A (en) METHOD FOR LABORATORY ASSESSMENT OF EFFECTIVENESS OF TREATMENT OF INTOXICATION IN RESUSCITATIVE PATIENTS
篠﨑 et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA
UA96331U (en) METHOD OF ASSESSMENT OF DISORDERS OF LIPID METABOLISM IN LYMPHOCYTES IN PATIENTS WITH ISCHEMIC HEART DISEASE
UA104711U (en) A method of predicting acute coronary syndrome in patients with stable coronary heart disease
UA87252U (en) Method for evaluation of lipid disorders in patients with permanent form of atrial fibrillation
RU2016152782A (en) METHOD FOR PREVENTION OF DISORDERS OF MENSTRUAL FUNCTION IN GIRLS
CL2013003070A1 (en) 3-carboxy-n-ethyl-n, n-dimethylpropan-1-ammonium salts (2e) -3-carboxy acrylate, phosphatodihydrogen and 2,6-diohydyl-1,2,3,6-tetrahydropyrimidine-4-carboxylate; preparation procedure; and use in the treatment of cardiovascular diseases.
RU2014119325A (en) A method for predicting the risk of chronic atrial fibrillation in patients with cardiovascular disease

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140504